![Jeffrey Rudy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Rudy
Keine laufenden Positionen mehr
Karriereverlauf von Jeffrey Rudy
Ehemalige bekannte Positionen von Jeffrey Rudy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CAPRICOR THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - | - |
AMGEN INC. | Corporate Officer/Principal | - | - |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - | - |
Agouron Pharmaceuticals LLC
![]() Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
PFIZER, INC. | Corporate Officer/Principal | - | - |
Celladon Corp.
![]() Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | - |
Anaborex, Inc.
![]() Anaborex, Inc. Medical/Nursing ServicesHealth Services Anaborex, Inc. provides clinical research services for metabolic diseases. The company develops drugs for the treatment of cancer related wasting syndrome. It was founded in 2005 by Alan Saven and Jorge Nieva and is located in La Jolla, CA | Geschäftsführer | - | 25.03.2010 |
Corporate Officer/Principal | 25.03.2010 | 01.10.2012 |
Ausbildung von Jeffrey Rudy
The Ohio State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Corporate Officer/Principal | 6 |
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 8 |
Health Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
PFIZER, INC. | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
AMGEN INC. | Health Technology |
CAPRICOR THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Anaborex, Inc.
![]() Anaborex, Inc. Medical/Nursing ServicesHealth Services Anaborex, Inc. provides clinical research services for metabolic diseases. The company develops drugs for the treatment of cancer related wasting syndrome. It was founded in 2005 by Alan Saven and Jorge Nieva and is located in La Jolla, CA | Health Services |
Celladon Corp.
![]() Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Agouron Pharmaceuticals LLC
![]() Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Cell Genesys, Inc.
![]() Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Börse
- Insiders
- Jeffrey Rudy
- Erfahrung